Cargando…

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma

BACKGROUND: The therapeutic effect of immune checkpoint blockers, especially the neutralizing antibodies of programmed cell death (PD-1) and its ligand programmed death ligand 1 (PD-L1), has been well verified in melanoma. Nevertheless, the dissatisfactory response rate and the occurrence of resista...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Weinan, Ma, Jinyuan, Guo, Sen, Wang, Huina, Wang, Sijia, Shi, Qiong, Liu, Lin, Zhao, Tao, Yang, Fengfan, Chen, Shuyang, Chen, Jianru, Zhao, Jianhong, Yu, Chen, Yi, Xiuli, Yang, Yuqi, Ma, Jingjing, Ni, Qingrong, Zhu, Guannan, Gao, Tianwen, Li, Chunying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733187/ https://www.ncbi.nlm.nih.gov/pubmed/33298620 http://dx.doi.org/10.1136/jitc-2020-001866

Ejemplares similares

Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis
por: Guo, Weinan, et al.
Publicado: (2022)

A20 promotes melanoma progression via the activation of Akt pathway
por: Ma, Jinyuan, et al.
Publicado: (2020)

Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
por: Shi, Qiong, et al.
Publicado: (2022)

SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR activation
por: Yi, Xiuli, et al.
Publicado: (2023)

PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer
por: Shen, Yang, et al.
Publicado: (2020)

Down-regulated miR-23a Contributes to the Metastasis of Cutaneous Melanoma by Promoting Autophagy
por: Guo, Weinan, et al.
Publicado: (2017)

Up‐regulated deubiquitinase USP4 plays an oncogenic role in melanoma
por: Guo, Weinan, et al.
Publicado: (2018)

Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation
por: Qin, Rui, et al.
Publicado: (2021)

Impact of Interferon-alpha1b (IFN-α1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma
por: Liu, Yu, et al.
Publicado: (2020)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

SIRT3-Dependent Mitochondrial Dynamics Remodeling Contributes to Oxidative Stress-Induced Melanocyte Degeneration in Vitiligo
por: Yi, Xiuli, et al.
Publicado: (2019)

Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer
por: Li, Gaopeng, et al.
Publicado: (2021)

AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells
por: Zhang, Ganggang, et al.
Publicado: (2023)

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021)

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers
por: Hu, Chunhong, et al.
Publicado: (2021)

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
por: Wang, Minglei, et al.
Publicado: (2023)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFκB axis
por: Sun, Mayu, et al.
Publicado: (2021)

circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape
por: Dong, Li-Feng, et al.
Publicado: (2023)

Long Non-Coding RNA CD27-AS1-208 Facilitates Melanoma Progression by Activating STAT3 Pathway
por: Ma, Jingjing, et al.
Publicado: (2022)

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
por: Zhang, Wenjie, et al.
Publicado: (2020)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1
por: Chen, Zhanfei, et al.
Publicado: (2020)

Targeting Wnt/β-Catenin Signaling Exacerbates Ferroptosis and Increases the Efficacy of Melanoma Immunotherapy via the Regulation of MITF
por: Wang, Hao, et al.
Publicado: (2022)

Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
por: Zhu, Lin, et al.
Publicado: (2022)

A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy
por: Sánchez-Alonso, Santiago, et al.
Publicado: (2020)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression
por: Lv, Tingting, et al.
Publicado: (2022)

POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation
por: Liu, Lin, et al.
Publicado: (2020)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma
por: Zhou, Jiayi, et al.
Publicado: (2021)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation
por: Liu, Shuangqing, et al.
Publicado: (2021)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Kortekaas, Kim E, et al.
Publicado: (2021)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes
por: Lu, Chunwan, et al.
Publicado: (2022)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jjlgrbnli8uettoprnb4duji9i